Article Listing - Exelixis and Sanofi terminate $1 billion cancer deal

FERMENTA INTO LOSS

6 April 1992

Swedish drugmaker Fermenta reported a 1.23 billion kroner ($203.4 million) loss for 1991, compared with a loss of 599 million...

STOCK MARKET COMMENTARY: NEW YORK

6 April 1992

NEW YORK: share prices moved up and down during the reporting week, first with lower car sales pushing the Dow...

US MEDICAID REBATES AND "BEST PRICES"

6 April 1992

Eliminating the "best price" provision from the US Medicaid rebate formula for the top 100 single-source and innovator multiple-source drugs...

COMPANY NEWS FROM CHINA

6 April 1992

The Shanghai Medicines and Health Products Import and Export Corporation of China exported products worth $150 million in 1991, reports...

NEW PRES AT RHONE-POULENC RORER

6 April 1992

Rhone-Poulenc Rorer Inc has named Manfred Karobath as senior vice president, RPR, and president, RPR Research and Development. He was...

NEW PRES AT PROCORDIA

6 April 1992

Jan Ekberg has been named as president and chief executive at Procordia, in succession to Soren Gyll who has become...

BTG SALE COMPLETED

6 April 1992

The sale of British Technology Group by the UK government to a management and employee buy-out consortium was completed at...

AUSTRALIAN LAUNCH OF ROCHE'S AURORIX

6 April 1992

Hoffmann-La Roche's reversible inhibitor of monoamine oxidase type A, Aurorix (moclobemide) has now been launched in Australia. The novel antidepressant...

AMA REPORT ON CONTRACEPTIVES

6 April 1992

The outcome of a report from the American Medical Association's Board of Trustees concludes that long-acting contraceptives may be medically...

ICN-GALENIKA "HEALTHY SHARES"

6 April 1992

Yugoslavia's Tanjug news agency reports that Milan Panic, head of ICN-Galenika and founder of US-based ICN Pharmaceuticals, is saying the...

Showing 94511-94520 of 95365 articles